Literature DB >> 6210439

Macrophage fibrinolytic activity: identification of two pathways of plasmin formation by intact cells and of a plasminogen activator inhibitor.

H A Chapman, Z Vavrin, J B Hibbs.   

Abstract

Endotoxin-stimulated macrophages hydrolyze fibrin by a plasmin-mediated process in the absence of detectable soluble plasminogen activator (PAs). The data show that macrophages also activate plasmin by a membrane-associated plasminogen activator (PAm). In the presence of endotoxin, PAm activity increases, and plasmin is formed only by PAm. In addition, endotoxin stimulates macrophages to secrete a proteinase inhibitor that blocks PAs activity but not PAm or plasmin activity. The increased PAm activity and the PA inhibitor secretion in response to endotoxin explains the ability of intact macrophages to hydrolyze fibrin in the absence of detectable PAs. Endotoxin, 100 ng/ml, induced an intracellular PA inhibitor in cultured macrophages, and this correlated with accumulation of inhibitor in medium over the cells. The intracellular PA inhibitor was found to be 50--60 kilodaltons by gel chromatography, to be of anionic charge at pH 7.4 and to inhibit urokinase esterolytic and proteolytic activity but not preformed plasmin. These results define two pathways of plasmin formation by intact macrophages and identify the macrophage cell surface as a site of PA activity relatively protected from soluble proteinase inhibitors.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6210439     DOI: 10.1016/0092-8674(82)90220-3

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  44 in total

1.  The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival.

Authors:  K M Dougherty; J M Pearson; A Y Yang; R J Westrick; M S Baker; D Ginsburg
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

2.  Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome.

Authors:  S Idell; K K James; E G Levin; B S Schwartz; N Manchanda; R J Maunder; T R Martin; J McLarty; D S Fair
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

3.  Effect of polymyxin B and colimycin on induction of plasminogen antiactivator by lipopolysaccharide in human endothelial cell culture.

Authors:  F Dubor; A M Dosne; L A Chedid
Journal:  Infect Immun       Date:  1986-06       Impact factor: 3.441

4.  Urokinase has direct catalytic activity against fibrinogen and renders it less clottable by thrombin.

Authors:  J I Weitz; B Leslie
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

5.  Characterization of a macrophage-derived plasminogen-activator inhibitor. Similarities with placental urokinase inhibitor.

Authors:  H A Chapman; O L Stone
Journal:  Biochem J       Date:  1985-08-15       Impact factor: 3.857

6.  Plasminogen activator inhibitor-1: a novel therapeutic target for hypertension?

Authors:  Daniel I Simon; Norman M Simon
Journal:  Circulation       Date:  2013-10-03       Impact factor: 29.690

7.  An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines.

Authors:  A R Nusrat; H A Chapman
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

8.  Plasminogen activation in healing human wounds.

Authors:  B M Schäfer; K Maier; U Eickhoff; R F Todd; M D Kramer
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

9.  The urokinase receptor is required for human monocyte chemotaxis in vitro.

Authors:  M R Gyetko; R F Todd; C C Wilkinson; R G Sitrin
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

10.  Regulatory elements involved in constitutive and phorbol ester-inducible expression of the plasminogen activator inhibitor type 2 gene promoter.

Authors:  E Cousin; R L Medcalf; G E Bergonzelli; E K Kruithof
Journal:  Nucleic Acids Res       Date:  1991-07-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.